KEGG   PATHWAY: ko04933
Entry
ko04933                     Pathway                                
Name
AGE-RAGE signaling pathway in diabetic complications
Description
Advanced glycation end products (AGEs) are a complex group of compounds produced through the non-enzymatic glycation and oxidation of proteins, lipids and nucleic acids, primarily due to aging and under certain pathologic condition such as huperglycemia. Some of the best chemically characterized AGEs include N-epsilon-carboxy-methyl-lysine (CML), N-epsilon-carboxy-ethyl-lysine (CEL), and Imidazolone. The major receptor for AGEs, known as receptor for advanced glycation end products (RAGE or AGER), belongs to the immunoglobulin superfamily and has been described as a pattern recognition receptor. AGE/RAGE signaling elicits activation of multiple intracellular signal pathways involving NADPH oxidase, protein kinase C, and MAPKs, then resulting in NF-kappaB activity. NF-kappa B promotes the expression of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-alpha and a variety of atherosclerosis-related genes, including VCAM-1, tissue factor, VEGF, and RAGE. In addition, JAK-STAT-mediated and PI3K-Akt-dependent pathways are induced via RAGE, which in turn participate in cell proliferation and apoptosis respectively. Hypoxia-mediated induction of Egr-1 was also shown to require the AGE-RAGE interaction. The results of these signal transductions have been reported to be the possible mechanism that initates diabetic complications.
Class
Human Diseases; Endocrine and metabolic disease
Pathway map
ko04933  AGE-RAGE signaling pathway in diabetic complications
ko04933

Other DBs
GO: 1904603
Orthology
K00922  PIK3CA_B_D; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta [EC:2.7.1.153]
K01116  PLCG1; phosphatidylinositol phospholipase C, gamma-1 [EC:3.1.4.11]
K01398  MMP2; matrix metalloproteinase-2 (gelatinase A) [EC:3.4.24.24]
K02089  CDK4; cyclin-dependent kinase 4 [EC:2.7.11.22]
K02159  BAX; apoptosis regulator BAX
K02161  BCL2; apoptosis regulator Bcl-2
K02187  CASP3; caspase 3 [EC:3.4.22.56]
K02580  NFKB1; nuclear factor NF-kappa-B p105 subunit
K02649  PIK3R1_2_3; phosphoinositide-3-kinase regulatory subunit alpha/beta/delta
K02677  PRKCA; classical protein kinase C alpha type [EC:2.7.11.13]
K02833  HRAS; GTPase HRas
K03156  TNF, TNFA; tumor necrosis factor superfamily, member 2
K03901  F3, CD142; coagulation factor III (tissue factor)
K03907  THBD, CD141; thrombomodulin
K03982  SERPINE1, PAI1; plasminogen activator inhibitor 1
K04166  AGTR1; angiotensin II receptor type 1
K04371  ERK, MAPK1_3; mitogen-activated protein kinase 1/3 [EC:2.7.11.24]
K04383  IL1A; interleukin 1 alpha
K04388  TGFBR2; TGF-beta receptor type-2 [EC:2.7.11.30]
K04392  RAC1; Ras-related C3 botulinum toxin substrate 1
K04393  CDC42; cell division control protein 42
K04440  JNK; mitogen-activated protein kinase 8/9/10 (c-Jun N-terminal kinase) [EC:2.7.11.24]
K04441  P38; p38 MAP kinase [EC:2.7.11.24]
K04446  NFATC1, NFAT2, NFATC; nuclear factor of activated T-cells, cytoplasmic 1
K04447  JAK2; Janus kinase 2 [EC:2.7.10.2]
K04448  JUN; transcription factor AP-1
K04456  AKT; RAC serine/threonine-protein kinase [EC:2.7.11.1]
K04500  SMAD2; mothers against decapentaplegic homolog 2
K04501  SMAD4; mothers against decapentaplegic homolog 4
K04503  CCND1; G1/S-specific cyclin-D1
K04519  IL1B; interleukin 1 beta
K04674  TGFBR1, ALK5; TGF-beta receptor type-1 [EC:2.7.11.30]
K04692  STAT3; signal transducer and activator of transcription 3
K04702  PIM1; proto-oncogene serine/threonine-protein kinase Pim-1 [EC:2.7.11.1]
K04735  RELA; transcription factor p65
K05405  IL6; interleukin 6
K05448  VEGFA; vascular endothelial growth factor A
K05449  VEGFC_D; vascular endothelial growth factor C/D
K05717  FN1; fibronectin 1
K05740  DIAPH1; diaphanous 1
K05857  PLCD; phosphatidylinositol phospholipase C, delta [EC:3.1.4.11]
K05858  PLCB; phosphatidylinositol phospholipase C, beta [EC:3.1.4.11]
K05859  PLCG2; phosphatidylinositol phospholipase C, gamma-2 [EC:3.1.4.11]
K05860  PLCE; phosphatidylinositol phospholipase C, epsilon [EC:3.1.4.11]
K06068  PRKCD; novel protein kinase C delta type [EC:2.7.11.13]
K06236  COL1A; collagen type I alpha
K06237  COL4A; collagen type IV alpha
K06490  ICAM1, CD54; intercellular adhesion molecule 1
K06494  SELE, CD62E; selectin, endothelial cell
K06527  VCAM1, CD106; vascular cell adhesion molecule 1
K06624  CDKN1B, P27, KIP1; cyclin-dependent kinase inhibitor 1B
K07201  FOXO1; forkhead box protein O1
K07827  KRAS, KRAS2; GTPase KRas
K07828  NRAS; GTPase NRas
K08008  NOX1, MOX1; NADPH oxidase 1
K09203  EGR1; early growth response protein 1
K09821  AGT, SERPINA8; angiotensinogen
K10030  IL8, CXCL8; interleukin 8
K11220  STAT1; signal transducer and activator of transcription 1
K11223  STAT5A; signal transducer and activator of transcription 5A
K11224  STAT5B; signal transducer and activator of transcription 5B
K13242  NOS3; nitric-oxide synthase, endothelial [EC:1.14.13.39]
K13375  TGFB1; transforming growth factor beta-1
K13376  TGFB2; transforming growth factor beta-2
K13377  TGFB3; transforming growth factor beta-3
K14624  CCL2, MCP1; C-C motif chemokine 2
K16366  EDN1; endothelin-1
K16858  VEGFB; vascular endothelial growth factor B
K18050  PRKCE; novel protein kinase C epsilon type [EC:2.7.11.13]
K18952  PRKCZ; atypical protein kinase C zeta type [EC:2.7.11.13]
K19662  PRKCB; classical protein kinase C beta type [EC:2.7.11.13]
K19720  COL3A; collagen type III alpha
K19722  AGER, RAGE; receptor for advanced glycosylation end products
K21421  NOX2, GP91, CYBB; NADPH oxidase 2 [EC:1.-.-.-]
K21423  NOX4, RENOX; NADPH oxidase 4 [EC:1.6.3.-]
K23605  SMAD3; mothers against decapentaplegic homolog 3
Compound
C00031  D-Glucose
C00076  Calcium cation
C00165  Diacylglycerol
C00195  N-Acylsphingosine
C01245  D-myo-Inositol 1,4,5-trisphosphate
C21011  [Protein]-N(epsilon)-(carboxymethyl)lysine
C21012  [Protein]-N(epsilon)-(carboxyethyl)lysine
C21013  [Protein]-pyrraline
C21014  [Protein]-pentosidine
Reference
  Authors
Kanwar YS, Sun L, Xie P, Liu FY, Chen S
  Title
A glimpse of various pathogenetic mechanisms of diabetic nephropathy.
  Journal
Annu Rev Pathol 6:395-423 (2011)
DOI:10.1146/annurev.pathol.4.110807.092150
Reference
  Authors
Yamagishi S
  Title
Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
  Journal
Exp Gerontol 46:217-24 (2011)
DOI:10.1016/j.exger.2010.11.007
Reference
  Authors
Roy B
  Title
Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures.
  Journal
World J Diabetes 4:101-13 (2013)
DOI:10.4239/wjd.v4.i4.101
Reference
  Authors
Hegab Z, Gibbons S, Neyses L, Mamas MA
  Title
Role of advanced glycation end products in cardiovascular disease.
  Journal
World J Cardiol 4:90-102 (2012)
DOI:10.4330/wjc.v4.i4.90
Reference
  Authors
Calcutt NA, Cooper ME, Kern TS, Schmidt AM
  Title
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials.
  Journal
Nat Rev Drug Discov 8:417-29 (2009)
DOI:10.1038/nrd2476
Reference
  Authors
Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY
  Title
Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells.
  Journal
Reference
  Authors
Meloche J, Paulin R, Courboulin A, Lambert C, Barrier M, Bonnet P, Bisserier M, Roy M, Sussman MA, Agharazii M, Bonnet S
  Title
RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.
  Journal
Arterioscler Thromb Vasc Biol 31:2114-24 (2011)
DOI:10.1161/ATVBAHA.111.230573
Reference
  Authors
Guh JY, Huang JS, Chen HC, Hung WC, Lai YH, Chuang LY
  Title
Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1.
  Journal
Am J Kidney Dis 38:1096-104 (2001)
DOI:10.1053/ajkd.2001.28616
Reference
  Authors
Goldin A, Beckman JA, Schmidt AM, Creager MA
  Title
Advanced glycation end products: sparking the development of diabetic vascular injury.
  Journal
Circulation 114:597-605 (2006)
DOI:10.1161/CIRCULATIONAHA.106.621854
Reference
  Authors
Zong H, Ward M, Stitt AW
  Title
AGEs, RAGE, and diabetic retinopathy.
  Journal
Curr Diab Rep 11:244-52 (2011)
DOI:10.1007/s11892-011-0198-7
Reference
  Authors
Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S
  Title
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
  Journal
Biochim Biophys Acta 1820:663-71 (2012)
DOI:10.1016/j.bbagen.2011.03.014
Reference
  Authors
Shi L, Yu X, Yang H, Wu X
  Title
Advanced glycation end products induce human corneal epithelial cells apoptosis through generation of reactive oxygen species and activation of JNK and p38 MAPK pathways.
  Journal
PLoS One 8:e66781 (2013)
DOI:10.1371/journal.pone.0066781
Reference
  Authors
Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, Graves DT
  Title
Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor.
  Journal
Am J Physiol Cell Physiol 292:C850-6 (2007)
DOI:10.1152/ajpcell.00356.2006
Reference
  Authors
Alikhani M, Roy S, Graves DT
  Title
FOXO1 plays an essential role in apoptosis of retinal pericytes.
  Journal
Mol Vis 16:408-15 (2010)
Reference
  Authors
Sheikpranbabu S, Haribalaganesh R, Lee KJ, Gurunathan S
  Title
Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability.
  Journal
Biochimie 92:1040-51 (2010)
DOI:10.1016/j.biochi.2010.05.004
Reference
  Authors
Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, D'Agati V, Schmidt AM
  Title
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42.
  Journal
J Biol Chem 283:34457-68 (2008)
DOI:10.1074/jbc.M801465200
Reference
  Authors
Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L
  Title
Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion.
  Journal
Diabetes 50:1495-504 (2001)
DOI:10.2337/diabetes.50.6.1495
Reference
  Authors
Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY
  Title
Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.
  Journal
FASEB J 18:176-8 (2004)
DOI:10.1096/fj.02-1117fje
Reference
  Authors
Chang JS, Wendt T, Qu W, Kong L, Zou YS, Schmidt AM, Yan SF
  Title
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products.
  Journal
Circ Res 102:905-13 (2008)
DOI:10.1161/CIRCRESAHA.107.165308
Reference
  Authors
Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S
  Title
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction.
  Journal
Kidney Int 66:2137-47 (2004)
DOI:10.1111/j.1523-1755.2004.66004.x
Related
pathway
ko04010  MAPK signaling pathway
ko04020  Calcium signaling pathway
ko04110  Cell cycle
ko04151  PI3K-Akt signaling pathway
ko04350  TGF-beta signaling pathway
ko04614  Renin-angiotensin system
ko04630  JAK-STAT signaling pathway

DBGET integrated database retrieval system